Objective Impaired megakaryocyte maturation and insufficient platelet production participate in the pathogenesis of primary immune thrombocytopenia (ITP).The demethylating agent,decitabine (DAC) has been used in the management of myelodysplastic syndrome (MDS) with a moderate response in thrombocytopenia.DAC is known to promote cell differentiation and maturation at low doses.However,the effect of DAC on megakaryocyte maturation and platelet production in ITP has not been reported.